In summary, the addition of the IRAK4 inhibitor emavusertib was beneficial to the anti-tumor activity of PI3K and BTK inhibitors and it can also overcome the acquired resistance in MZL models. This evidence concerns the gene BTK and marginal zone lymphoma.